

What do AstraZeneca's (AZ) negative MYSTIC trial results mean for other anti-CTLA-4 antibody developers?

AZ's Tremelimumab is an IgG2 antibody which has a different mechanism of action than IgG1 anti-CTLA-4 antibodies. The only approved anti-CTLA-4 antibody is BMS's Yervoy®, which is an IgG1.

Agenus' anti-CTLA-4, AGEN1884, is also an IgG1 with demonstrated clinical and pharmacologic comparability to Yervoy.

We see the MYSTIC trial negative result as a positive for Agenus for the following reasons:

- Other than Yervoy, AGEN1884 is the most clinically advanced anti-CTLA-4 antibody that has a differentiated mechanism of action as compared to Tremelimumab
- We have shown that an IgG1 anti-CTLA-4 antibody provides more than just blockade of the CTLA-4 receptor ([Reference](#)). We also recently published that, in addition to blocking CTLA-4, AGEN1884 promotes [FcγR-dependent anti-tumor mechanisms](#) which is expected to provide superior therapeutic benefit to IgG2 antibodies. These studies further highlight the advantages of an IgG1 (like a Yervoy) over an IgG2 (like a Tremelimumab).

Agenus' CTLA-4 and PD-1 Antibodies Are Advancing Towards Potential BLA in 2L Cervical Cancer

- Our proprietary antibodies that bind to these validated targets—AGEN1884 (anti-CTLA4 IgG1) and AGEN2034 (an anti-PD-1 antibody)—are the most advanced clinical stage combination with registrational potential in 2L cervical cancer.
- Agenus' strategy in cervical cancer is to submit potential BLA filings for both PD-1 monotherapy and combination therapy as early as 2020
- For recent clinical data on this combination, please see [here](#).

CTLA-4 remains attractive for future Agenus I-O combinations

- In summary, we believe that the value of our anti-CTLA-4 antibody is supported by underlying scientific rationale – importantly, biological advantages of an IgG1 vs IgG2 backbone and prior clinical validation remains intact.

Contact

Agenus Inc. • Jennifer Buell, PhD • 781-674-4420 • Jennifer.Buell@agenusbio.com

Forward-Looking Statements: This release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.